PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34359638-0 2021 Gemcitabine Plus Nab-Paclitaxel Induces PD-L1 mRNA Expression in Plasma-Derived Microvesicles in Pancreatic Cancer. nab 17-20 CD274 molecule Homo sapiens 40-45 33475294-4 2021 Based on IMpassion130, the combination of atezolizumab and nab-paclitaxel is now considered a standard of care for the treatment of PD-L1-positive advanced TNBC. nab 59-62 CD274 molecule Homo sapiens 132-137 35619841-5 2022 We report a case of a 74-year-old male with stage four (IV) BSCC of the lung who experienced a complete metabolic with partial anatomic response to combined chemotherapy and immunotherapy with carboplatin/nab-paclitaxel/pembrolizumab and has continued to be in partial remission on maintenance immunotherapy with pembrolizumab despite PD-L1-negative status. nab 205-208 CD274 molecule Homo sapiens 335-340 32988260-2 2020 In March 2019, the combination of nab-paclitaxel and atezolizumab was approved by the US FDA for patients with PD-L1 positive metastatic triple-negative breast cancer based on positive results of the Impassion130 trial. nab 34-37 CD274 molecule Homo sapiens 111-116 31612909-10 2019 In the PD-L1-positive subgroup, median PFS was 10.8 months (atezo + nab-P) versus 3.8 months (plac + nab-P; HR, 0.04; 95% CI, <0.01-0.35). nab 68-71 CD274 molecule Homo sapiens 7-12 32450725-3 2020 The results of the IMpassion130 trial have recently led to the approval of the combination of atezolizumab and nab-paclitaxel in the first-line treatment of patients with unresectable locally advanced or metastatic, PD-L1-positive TNBC. nab 111-114 CD274 molecule Homo sapiens 216-221 32426048-7 2020 Results: Our results demonstrated that atezolizumab plus nab-paclitaxel augmented versus nab-paclitaxel therapy cost $104,278 and $149,465 and yielded an additional 0.371 and 0.762 of quality-adjusted life year (QALY) in in all patients with unknown PD-L1 status and subpopulation with PD-L1-positive, respectively, which led to an ICER of $281,448 and $196,073 per QALY gained. nab 57-60 CD274 molecule Homo sapiens 250-255 32426048-7 2020 Results: Our results demonstrated that atezolizumab plus nab-paclitaxel augmented versus nab-paclitaxel therapy cost $104,278 and $149,465 and yielded an additional 0.371 and 0.762 of quality-adjusted life year (QALY) in in all patients with unknown PD-L1 status and subpopulation with PD-L1-positive, respectively, which led to an ICER of $281,448 and $196,073 per QALY gained. nab 57-60 CD274 molecule Homo sapiens 286-291 32426048-11 2020 Conclusion: The atezolizumab plus nab-paclitaxel treatment is likely to be a cost-effective option compared with chemotherapy based on nab-paclitaxel for the patients with PD-L1-positive advanced TNBC. nab 34-37 CD274 molecule Homo sapiens 172-177 32408327-0 2020 [A Case of Squamous Cell Lung Cancer in an Elderly Patient with Low PD-L1 Expression Effectively Treated with Nab-Paclitaxel(Nab-PTX)plus Carboplatin (CBDCA)plus Pembrolizumab for a Recurrence after Operation]. nab 110-113 CD274 molecule Homo sapiens 68-73 32408327-6 2020 Chemotherapy using nab-PTX plus CBDCA plus pembrolizumab may become one of the therapeutic choices for the recurrence after operation of an elderly person with squamous cell lung carcinoma and low PD-L1 expression. nab 19-22 CD274 molecule Homo sapiens 197-202 32129476-2 2020 Patients with metastatic or locally advanced TNBC with PD-L1 expression on immune cells occupying >=1% of tumor area demonstrated survival benefit with the addition of atezolizumab to nab-paclitaxel. nab 184-187 CD274 molecule Homo sapiens 55-60 32042863-6 2019 Biomarkers will allow clinicians to practice a precision medicine approach in ICBs (biomarker-based patient selection) such as treating triple-negative breast cancer patients that exhibit PD-L1 staining of tumor-infiltrating immune cells in >=1% of the tumor area with nanoparticle albumin-bound (nab)-paclitaxel plus anti-PD-L1 and treating patients of MSI-H or MMR deficient unresectable or metastatic solid tumors with pembrolizumab (anti-PD-1). nab 297-300 CD274 molecule Homo sapiens 188-193 31839159-6 2019 Combination of atezolizumab with nab-paclitaxel in a phase III study has recently seen success in terms of improved progression free and overall survival for the PD-L1 -positive population of metastatic TNBC in the first line/newly relapsed setting [3]. nab 33-36 CD274 molecule Homo sapiens 162-167 31842957-14 2019 In addition to the recently approved combination of atezolizumab and nab-paclitaxel for PD-L1-positive mTNBC, new treatments resulting in durable clinical responses, prolonged survival, and manageable safety profile would greatly benefit patients with mTNBC. nab 69-72 CD274 molecule Homo sapiens 88-93 31231572-6 2019 For patients with PD-L1-positive tumours (PD-L1 expression on tumour-infiltrating immune cells >=1%), we recommend first-line treatment with nab-paclitaxel and atezolizumab, when available. nab 144-147 CD274 molecule Homo sapiens 18-23 30345906-11 2018 CONCLUSIONS: Atezolizumab plus nab-paclitaxel prolonged progression-free survival among patients with metastatic triple-negative breast cancer in both the intention-to-treat population and the PD-L1-positive subgroup. nab 31-34 CD274 molecule Homo sapiens 193-198 27930644-5 2016 In combination with nab-paclitaxel, confirmed response rates were 46% in a PD-L1-unselected population in the first-line metastatic triple-negative breast cancer setting. nab 20-23 CD274 molecule Homo sapiens 75-80